Axon Enterprise, Inc (NASDAQ:AXON) Receives $815.00 Average Target Price from Brokerages

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have received a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $802.7143.

Several research firms have recently issued reports on AXON. JMP Securities reissued a “market outperform” rating and set a $825.00 target price on shares of Axon Enterprise in a research note on Monday, September 29th. Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a report on Wednesday, September 24th. Barclays decreased their price objective on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Royal Bank Of Canada began coverage on shares of Axon Enterprise in a research note on Monday, November 17th. They set an “outperform” rating and a $860.00 target price on the stock. Finally, Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $563.28 on Tuesday. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $610.39 and a 200-day moving average price of $709.16. The company has a market cap of $44.45 billion, a price-to-earnings ratio of 178.25, a price-to-earnings-growth ratio of 126.32 and a beta of 1.40. Axon Enterprise has a 12 month low of $469.24 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 EPS. As a group, equities analysts anticipate that Axon Enterprise will post 5.8 EPS for the current year.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the transaction, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the transaction, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 64,406 shares of company stock worth $38,521,038. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Stone House Investment Management LLC purchased a new position in Axon Enterprise during the third quarter valued at $29,000. New Millennium Group LLC bought a new position in shares of Axon Enterprise during the third quarter valued at $29,000. Banque Transatlantique SA bought a new position in shares of Axon Enterprise during the first quarter valued at $31,000. Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise in the 1st quarter worth about $33,000. Finally, Hemington Wealth Management raised its position in shares of Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 17 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.